In vitro identification of cytochrome P450 enzymes responsible for drug metabolism

Methods in Molecular Biology

Volumn 1015, Issue , 2013, Pages 251-261

  Yan, Zhengyin ^a   Caldwell, Gary W ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CYPs; Cytochrome P450; Metabolism; Phenotyping

Indexed keywords

BUFURALOL; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; DIETHYLDITHIOCARBAMIC ACID; KETOCONAZOLE; MEPHENYTOIN; MONTELUKAST; PACLITAXEL; PHENACETIN; QUINIDINE; SULFAPHENAZOLE; TESTOSTERONE; THIOTEPA;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ELECTROSPRAY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; HUMANS; HYDROXYLATION; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84880339124     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-435-7_16     Document Type: Article

References (13)

1. Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449
2. Yan Z, Caldwell GW (2001) Metabolism profi ling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem 5:403-425
3. Rannug A, Alexandrie A-K, Persson I, Ingelman-Sundberg M (1995) Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: Regulation and toxicological signifi -cance. J Occup Environ Med 37:25-36
4. Murray M (2006) Role of CYP pharmacogenetics and drug-drug interactions in the effi cacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58:871-885
5. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS-E, Mizugaki M (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596-603
6. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Infl uence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526
7. Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AYH (2011) Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: A re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 36:1-16
8. Vermeir M, Hemeryck A, Cuyckens F, Francesch A, Bockx M, Van Houdt J, Steemans K, Mannens G, Aviles P, De Coster R (2009) In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 77:1642-1654
9. Yan Z, Caldwell GW (2004) Evaluation of cytochrome P450 inhibition in human liver microsomes. Optimization in Drug Discovery, Humana, Totowa, NJ, pp 231-244
10. Zhang H, Davis CD, Sinz MW, Rodrigues AD (2007) Cytochrome P450 reactionphenotyping: An industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687
11. Harper TW, Brassil PJ (2008) Reaction phenotyping: Current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 10:200-207
12. Kumar V, Rock DA, Warren CJ, Tracy TS, Wahlstrom JL (2006) Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 34:1903-1908
13. Yan Z, Caldwell GW, Wu W, McKown L, Rafferty B, Jones W, Masucci JA (2002) In vitro identifi cation of metabolic pathways and cytochrome P450 isoforms involved in the metabolism of etoperidone. Xenobiotica 32(11):949-962